- SG$598.63m
- SG$517.05m
- SG$78.18m
- 80
- 31
- 90
- 78
Annual cashflow statement for TalkMed, fiscal year end - December 31st, SGD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 24.8 | 27.3 | 36.8 | 37.8 | 49.4 |
| Depreciation | |||||
| Non-Cash Items | 6.32 | 0.776 | 3 | 1.77 | -16.4 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.36 | -7.39 | -5.1 | -0.647 | -7.36 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 31.3 | 23.2 | 37.3 | 41.7 | 28.8 |
| Capital Expenditures | -1.95 | -0.77 | -4.33 | -0.704 | -0.394 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -6.49 | -1.21 | -0.686 | 0 | 14.4 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -8.45 | -1.98 | -5.01 | -0.704 | 14 |
| Financing Cash Flow Items | 2.51 | 2.8 | 0 | 0.4 | 0 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -24.1 | -18.4 | -33.9 | -31.7 | -49.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.27 | 2.73 | -1.58 | 9.31 | -7.12 |